MX2018008624A - Metodo para tratar glomerulopatia c3. - Google Patents

Metodo para tratar glomerulopatia c3.

Info

Publication number
MX2018008624A
MX2018008624A MX2018008624A MX2018008624A MX2018008624A MX 2018008624 A MX2018008624 A MX 2018008624A MX 2018008624 A MX2018008624 A MX 2018008624A MX 2018008624 A MX2018008624 A MX 2018008624A MX 2018008624 A MX2018008624 A MX 2018008624A
Authority
MX
Mexico
Prior art keywords
glomerulopathy
treating
human
susceptible
administering
Prior art date
Application number
MX2018008624A
Other languages
English (en)
Inventor
Bekker Petrus
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2018008624A publication Critical patent/MX2018008624A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se proporcionan métodos para tratar un humano que padece de o es susceptible a glomerulopatía C3 que comprende administrar al humano una cantidad efectiva de un antagonista de C5aR.
MX2018008624A 2016-01-14 2017-01-12 Metodo para tratar glomerulopatia c3. MX2018008624A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662278788P 2016-01-14 2016-01-14
US201662280346P 2016-01-19 2016-01-19
US201662347450P 2016-06-08 2016-06-08
US201662397527P 2016-09-21 2016-09-21
PCT/US2017/013132 WO2017123716A1 (en) 2016-01-14 2017-01-12 Method of treating c3 glomerulopathy

Publications (1)

Publication Number Publication Date
MX2018008624A true MX2018008624A (es) 2018-12-10

Family

ID=59312069

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018008624A MX2018008624A (es) 2016-01-14 2017-01-12 Metodo para tratar glomerulopatia c3.
MX2022006069A MX2022006069A (es) 2016-01-14 2017-01-12 Metodo para tratar glomerulopatia c3.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022006069A MX2022006069A (es) 2016-01-14 2017-01-12 Metodo para tratar glomerulopatia c3.

Country Status (17)

Country Link
US (3) US20170202821A1 (es)
EP (1) EP3402486A4 (es)
JP (4) JP7339733B2 (es)
KR (1) KR20180102642A (es)
CN (1) CN108601790A (es)
AU (1) AU2017207359C1 (es)
BR (2) BR112018014222A2 (es)
CA (1) CA3010735C (es)
IL (1) IL260539B (es)
MA (1) MA43872A (es)
MX (2) MX2018008624A (es)
NZ (1) NZ744083A (es)
RU (1) RU2742888C2 (es)
SG (1) SG11201805828YA (es)
TW (1) TWI791423B (es)
WO (1) WO2017123716A1 (es)
ZA (1) ZA201804513B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI465434B (zh) 2008-12-22 2014-12-21 Chemocentryx Inc Ｃ５ａＲ拮抗劑
CN103068385B (zh) 2010-06-24 2015-04-29 凯莫森特里克斯股份有限公司 C5aR拮抗剂
SG11201702185UA (en) 2014-09-29 2017-04-27 Chemocentryx Inc PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
BR112018014222A2 (pt) 2016-01-14 2018-12-11 Chemocentryx, Inc. método de tratamento da glomerulopatia c3
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
IL303696A (en) 2017-03-01 2023-08-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
EP3658657A1 (en) * 2017-07-27 2020-06-03 Procter & Gamble International Operations SA. Phase-stable, sprayable freshening compositions comprising suspended particles
JP2021525860A (ja) * 2018-05-25 2021-09-27 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体代替経路関連腎症バイオマーカー
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
MX2021002640A (es) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
MX2021003425A (es) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
FI3886820T3 (fi) 2018-11-30 2023-05-25 Chemocentryx Inc Kapseliformulaatioita
KR20210137157A (ko) 2019-03-11 2021-11-17 인플라알엑스 게엠베하 C5a의 수용체 조절제로서의 융합된 피페리딘일 2고리 화합물 및 관련 화합물
CN116322683A (zh) * 2020-08-07 2023-06-23 科越医药(苏州)有限公司 作为c5ar抑制剂的化合物
MX2023007420A (es) * 2020-12-21 2023-06-29 Chemocentryx Inc Tratamiento de glomerulopatia c3 usando un inhibidor de c5a.
CN115192563B (zh) * 2022-05-09 2023-10-13 北京大学第一医院 C3a/C3aR通路拮抗剂治疗原发性膜性肾病的用途

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
RU2197288C2 (ru) * 1999-08-03 2003-01-27 Тверская медицинская академия Способ лечения больных хроническим гломерулонефритом
WO2002049993A2 (en) 2000-09-29 2002-06-27 Neurogen Corporation High affinity small molecule c5a receptor modulators
JP2003532726A (ja) 2000-05-05 2003-11-05 スミスクライン・ビーチャム・コーポレイション 新規抗感染症薬
JP5059275B2 (ja) 2000-08-10 2012-10-24 田辺三菱製薬株式会社 新規３置換尿素誘導体およびその医薬としての用途
KR100842791B1 (ko) 2000-09-14 2008-07-01 미쓰비시 타나베 파마 코퍼레이션 신규한 아미드 유도체 및 그의 의약적 용도
ATE360441T1 (de) 2001-08-17 2007-05-15 Tanox Inc Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
SI1427720T1 (sl) 2001-09-21 2009-08-31 Mitsubishi Tanabe Pharma Corp 3-substituirani-4-pirimidonski derivati
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
EP1487798A4 (en) 2002-03-28 2005-07-13 Neurogen Corp Substituted tetrahydroisoquinolines as C5A receptor modulators
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
WO2003084524A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US7138420B2 (en) 2002-08-08 2006-11-21 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
AU2003265625A1 (en) 2002-08-21 2004-03-11 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003290605A1 (en) 2002-11-05 2004-06-03 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
WO2004043925A2 (en) 2002-11-08 2004-05-27 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
EP1638935A1 (en) 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
WO2005007087A2 (en) 2003-07-03 2005-01-27 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EA200700117A1 (ru) 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CA2598423C (en) 2005-02-18 2014-05-27 Astrazeneca Ab Antibacterial piperidine derivatives
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
WO2007060215A2 (en) 2005-11-24 2007-05-31 Dompe' Pha.R.Ma S.P.A. (r)-arylkylamino derivatives and pharmaceutical compositions containing them
ES2612118T3 (es) 2006-03-15 2017-05-12 Alexion Pharmaceuticals, Inc. Tratamiento de pacientes de hemoglobinuria nocturna paroxística mediante un inhibidor del complemento
WO2008022060A2 (en) 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
EP2077842A2 (en) * 2006-10-31 2009-07-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an egfr antagonist for the treatment of glomerolonephritis
WO2009004650A1 (en) 2007-06-29 2009-01-08 Torrent Pharmaceuticals Ltd. Novel substituted piperidones as hsp inducers
EP2331525A4 (en) 2008-08-11 2013-01-02 Harvard College HALOFUGINONE ANALOGUES FOR THE INHIBITION OF ARNT SYNTHÉTASES AND USES THEREOF
EP2331561A4 (en) 2008-09-03 2013-02-27 Xenome Ltd PEPTIDE CONJUGATE LIBRARIES AND METHODS OF MAKING SAME
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
PL2894165T3 (pl) 2008-11-10 2023-04-17 Alexion Pharmaceuticals, Inc. Sposoby i kompozycje do leczenia zaburzeń układu dopełniacza
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
TWI465434B (zh) 2008-12-22 2014-12-21 Chemocentryx Inc Ｃ５ａＲ拮抗劑
US20120252792A1 (en) 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
CN103068385B (zh) 2010-06-24 2015-04-29 凯莫森特里克斯股份有限公司 C5aR拮抗剂
US8147400B1 (en) * 2011-01-17 2012-04-03 Coloplast A/S Penile implant with dilatant liquid
AU2013277154A1 (en) * 2012-06-20 2014-12-18 Jonathan E. Grob Complement pathway modulators and uses thereof
CN105392803B (zh) 2013-05-08 2019-12-06 诺和诺德股份有限公司 C5aR拮抗剂的用途
SG11201702185UA (en) 2014-09-29 2017-04-27 Chemocentryx Inc PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
BR112018014222A2 (pt) 2016-01-14 2018-12-11 Chemocentryx, Inc. método de tratamento da glomerulopatia c3
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
MX2023007420A (es) 2020-12-21 2023-06-29 Chemocentryx Inc Tratamiento de glomerulopatia c3 usando un inhibidor de c5a.

Also Published As

Publication number Publication date
US11779576B2 (en) 2023-10-10
RU2018129378A3 (es) 2020-05-20
US20220354837A1 (en) 2022-11-10
AU2017207359C1 (en) 2022-09-01
CA3010735C (en) 2023-06-13
KR20180102642A (ko) 2018-09-17
SG11201805828YA (en) 2018-08-30
CN108601790A (zh) 2018-09-28
NZ744083A (en) 2022-07-01
RU2018129378A (ru) 2020-02-14
JP2019501935A (ja) 2019-01-24
US11285138B2 (en) 2022-03-29
JP2024110998A (ja) 2024-08-16
EP3402486A4 (en) 2019-08-28
JP2021183625A (ja) 2021-12-02
BR122024002810A2 (pt) 2024-03-12
BR112018014222A2 (pt) 2018-12-11
MX2022006069A (es) 2023-01-12
RU2742888C2 (ru) 2021-02-11
MA43872A (fr) 2021-05-19
TWI791423B (zh) 2023-02-11
TW201726134A (zh) 2017-08-01
US20190201388A1 (en) 2019-07-04
US20170202821A1 (en) 2017-07-20
ZA201804513B (en) 2024-01-31
IL260539B (en) 2021-05-31
AU2017207359B2 (en) 2022-04-14
WO2017123716A1 (en) 2017-07-20
EP3402486A1 (en) 2018-11-21
JP7339733B2 (ja) 2023-09-06
JP2023126235A (ja) 2023-09-07
CA3010735A1 (en) 2017-07-20
AU2017207359A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
ZA201804513B (en) Method of treating c3 glomerulopathy
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
IL273959A (en) Methods and preparations for the treatment of rare diseases
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
MX2017010150A (es) Bacterias probioticas recombinantes.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
ZA201903873B (en) Methods of treating cochlear synaptopathy
MX2017000306A (es) Metodos para tratar hipotension.
NZ722600A (en) Methods of treating mild brain injury
WO2016094899A3 (en) Treatment of hmgb1-mediated inflammation
IL283069A (en) Methods of administering corticosteroids
EP4342544A3 (en) Enhancing the therapeutic activity of an immune checkpoint inhibitor
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
MX2019004804A (es) Tratamiento para el prurigo nodula.
IL284797A (en) Addiction treatment methods
MX2018001684A (es) Metodo de curacion de heridas.
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.